Amorphous Solid Dispersion Tablet

Assessment of API Recrystallization and Phase Distribution

Nano Carriers
Tablet

One approach to improve the solubility and bioavailability of poorly soluble drugs is to formulate the API in an amorphous state as an amorphous solid dispersion (ASD). Manufacturing of ASD based drug products involves complex mechanical and thermal transformations necessary to render the API in a kinetically stabilized amorphous state. However, detection and monitoring crystallization, either from residual crystalline API or crystallization of amorphous API, is extremely important in assessing the effectiveness of the formulation design and process.

Based on the qualitative insight obtained from two-dimensional correlative imaging techniques, this work quantified API crystallinity using 3D X-Ray Micro-Computed Tomography (Micro-CT). Login to learn more.

DigiM AI image analytics detecting recrystallization in an amorphous solid dispersion
Four images showing the original image, DigiM machine learning segmentation image result, low threshold image with noisy segmentation, and a high threshold image with failing to segment out the polymer and API.

Three modeled tablet samples composed of 20% indomethacin in copovidone (PVPVA) with similar drug loading and different levels of crystallinity  were imaged with various resolutions and contrast techniques. The massive amount of image data was processed with an artificial intelligence-based image segmentation engine. A suite of quantitative matrices was computed for not only the ASD domains and crystal API particles, but also pore space and pure polymer domains.

The data collected through this study can provide insight into the effectiveness of rendering the API in an amorphous state as well as the kinetic stabilization of the formulation.  The data also has the potential to predict drug release performance by combining these models with image-based computational physics, to measure effective diffusivity coefficient, disintegration pattern, as well as various designed release behavior. Upon continued improvements, such approaches can potentially result in drug product development efficiencies with respect to development time, material costs as well as reducing the burden of animal and/or clinical screening studies.

Our Expertise

In Numbers

95
+
%

Programs Supported

981
+
%

Formulations Digitized

22
+
%

Pharmaceutical Partners

stats background

Transform Your Program with Microstructure Science

Get started with a drug product digital twin.